Key clinical point: Haploidentical allogeneic transplantation is feasible and had an acceptable rate of non-relapse mortality, setting the stage for its use in future combination strategies.
Major finding: The cumulative risk of relapse and progression at 2 years was 56%, and the 1-year nonrelapse mortality was 21%.
Study details: A retrospective analysis including 96 patients who underwent haploidentical allogeneic hematopoietic stem cell transplantation between 2008 and 2016.
Disclosures: Authors reported no conflicts of interest.
Sahebi F, et al. Biol Blood Marrow Transplant. 2018 Sep 20. pii: S1083-8791(18)30575-5.
This Week's Must Reads
Must Reads in Multiple Myeloma
Ixazomib improves PFS after myeloma transplant, Dimopoulos MA et al. ASH 2018, Abstract 301
Study supports long-term survival in multiple myeloma subgroup, Usmani SZ et al. Blood Cancer J. 2018 Nov 23;8(12):123